Trevi Therapeutics Raises $50 Million Series C Financing Led by New Enterprise Associates
Company continuing the development of Nalbuphine® ER in chronic pruritus conditions New Haven, CT, July 20, 2017 – Trevi Therapeutics, Inc. (“Trevi” or the “Company”), announced today that the Company has completed a Series C financing of $50.5 million led […]